Dieses Forum nutzt Cookies
Dieses Forum verwendet Cookies, um deine Login-Informationen zu speichern, wenn du registriert bist, und deinen letzten Besuch, wenn du es nicht bist. Cookies sind kleine Textdokumente, die auf deinem Computer gespeichert sind; Die von diesem Forum gesetzten Cookies düfen nur auf dieser Website verwendet werden und stellen kein Sicherheitsrisiko dar. Cookies auf diesem Forum speichern auch die spezifischen Themen, die du gelesen hast und wann du zum letzten Mal gelesen hast. Bitte bestätige, ob du diese Cookies akzeptierst oder ablehnst.

Ein Cookie wird in deinem Browser unabhängig von der Wahl gespeichert, um zu verhindern, dass dir diese Frage erneut gestellt wird. Du kannst deine Cookie-Einstellungen jederzeit über den Link in der Fußzeile ändern.

Aptevo Therapeutics Inc.
WKN:APVO
#1
Notiz 

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

[Bild: APVOc0wl0852.png]


[Bild: chart.ashx?t=APVO&ty=c&ta=0&p=d&s=l]
#2
Notiz 

RE: Aptevo Therapeutics Inc.

Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting

https://finance.yahoo.com/news/aptevo-th...00684.html




The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies

Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Nov. 9)....
  • Aptevo Therapeutics Inc (NASDAQ: APVO) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients)
https://finance.yahoo.com/news/daily-bio...14764.html




Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial

Mon, November 9, 2020, 12:00 PM

Second Complete Remission Observed in a Patient in Cohort 6
Enrollment in Cohort 8 Has Started
SEATLLE, WA / ACCESSWIRE / November 9, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, today provided an update on its ongoing APVO436 Phase 1 clinical trial.
APVO436 is a novel anti-CD123 x anti-CD3 targeted investigational bispecific antibody therapy being evaluated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), in a Phase 1/1b open-label, dose-escalation study evaluating the safety and pharmacokinetic profile.
On Friday, November 6, Aptevo received preliminary data regarding cohort 6, which indicated complete remission in a second patient, in addition to the one previously announced. In total, there are now two patients with clinical remission in cohort 6. The data received also showed one patient exhibiting stable disease status, and six patients where the disease had progressed. A total of nine patients were listed in cohort 6 of the clinical trial......

https://finance.yahoo.com/news/aptevo-th...00458.html


Möglicherweise verwandte Themen…
Thema Verfasser Antworten Ansichten Letzter Beitrag
Notiz Five Prime Therapeutics boersenkater 2 1.254 02.08.2021, 08:35
Letzter Beitrag: boersenkater
Notiz Mirati Therapeutics Honnete 0 723 20.06.2021, 19:57
Letzter Beitrag: Honnete
Notiz Sarepta Therapeutics Ca$hmandt 1 1.460 08.01.2021, 20:29
Letzter Beitrag: Ca$hmandt

Gehe zu:


Benutzer, die gerade dieses Thema anschauen: 1 Gast/Gäste